Introduction {#s1}
============

Extracorporeal membrane oxygenation (ECMO) has been utilized in critically ill patients such as those with severe, reversible myocardial dysfunction and life-threatening respiratory failure. Patients on ECMO usually experience multi-organ failure and thus have high mortality [@pone.0042687-Lin1]. Independent prognostic factors and outcome scoring systems for predicting hospital mortality for patients on the first day of ECMO support [@pone.0042687-Lin2] and those already on ECMO support [@pone.0042687-Chen1] have been elucidated. However, outcome predictors for patients weaning from ECMO remain unclear.

Given promising new treatment methods bridged to a ventricular assist device or transplant and limited medical resources, investigators and physicians require reliable tools for monitoring and stratifying risk for critically ill patients in clinical practice and clinical trials. However, to date no study has clarified the relationship between patients being weaned from ECMO support and their short term prognosis. Therefore, this study investigated the prognostic factors and compared the accuracy of the Acute Physiology and Chronic Health Evaluation (APACHE) II [@pone.0042687-Knaus1], Sequential Organ Failure Assessment (SOFA) [@pone.0042687-Vincent1], Organ System Failure (OSF) number [@pone.0042687-Knaus2], and Acute Kidney Injury Network (AKIN) stages [@pone.0042687-Mehta1] for predicting hospital mortality and short-term prognosis in patients being weaned from ECMO support.

Materials and Methods {#s2}
=====================

Patient information and data collection {#s2a}
---------------------------------------

The Institutional Review Board at Chang Gung Memorial Hospital approved the study and waived the need for consent. All data in our study was anonymized. Between July 2006 and October 2010, 124 patients received ECMO support and experienced ECMO weaning via a 20-bed specialized cardiovascular surgery intensive care unit (CVS ICU). Those who were weaned off ECMO support but died within 48 hours (5 patients) were defined as unsuccessfully weaned and excluded. Medical records of 119 patients who were successfully weaned from ECMO support were examined.

The following retrospective data were obtained: demographic data; primary diagnosis for ECMO implementation; whether the patient was currently being weaned off ECMO support; APACHE II, SOFA score, and OSF number on the first day of ECMO support and the day of ECMO removal, respectively; AKIN stage (AKIN~48-hour~) at 48 hours post-ECMO removal; duration of hospitalization; and outcome. The primary study outcome was hospital mortality. Follow-up at 6 months after hospital discharge was performed via chart records.

Definitions {#s2b}
-----------

Successful weaning was defined as weaning from ECMO support followed by survival longer than 48 hours [@pone.0042687-Chen2]. Illness severity was assessed using APACHE II [@pone.0042687-Knaus1]. Physiological calculations utilized the worst physiological values on the first day of ECMO support and on the day of ECMO weaning. Organ function was assessed using SOFA score and OSF number, which were defined as in the original reports [@pone.0042687-Vincent1], [@pone.0042687-Knaus2]. Acute kidney injury was defined using the AKIN classification system, which requires at least two serum creatinine (SCr) values within 48 h [@pone.0042687-Mehta1]. The classification system comprises individual criteria for SCr levels and urine output (UO). A patient can fulfill the criteria by adjusting SCr concentrations, UO, or both. The baseline SCr concentration used for AKIN classification was that at the time of weaning off ECMO. The most anomalous values of each organ system on the first day of ECMO support and on the day of ECMO removal were recorded.

Clinical management {#s2c}
-------------------

The ECMO device (Medtronic, Inc., Anaheim, CA) comprised a centrifugal pump and a hollow-fiber microporous membrane oxygenator with an integrated heater. All ECMO circuits had a heparin-bound Carmeda bioactive surface. A hollow fiber oxygenator (Hilite LT 700; Medos, Aachen, Germany) or a silicone oxygenator (Medtronics, Minneapolis, MN, USA) was incorporated into the ECMO circuit. Percutaneous cannulation and cut-down procedures were necessary for some obese patients. According to the body size of the patient, a 17--19 Fr percutaneous arterial (outflow) cannulae and 19--21 percutaneous venous (inflow) cannulae (DLP; Medtronic Inc., Minneapolis, MN) were used. An 8 Fr distal perfusion catheter was implanted into the ipsilateral superficial femoral artery if the cannulated limb showed cyanosis.

For all patients, receiving ECMO support at least 48 hours before weaning was attempted. If the patient\'s hemodynamic and general condition became stable with echocardiographic evidence of improvement in left ventricular contractility (\>40% of left ventricular ejection fraction), an inotropic agent was then carefully tapered. Moreover, the oxygen saturation was continuously monitored until the mixed venous oxygen saturation was more than 70% without any deterioration in hemodynamic status, and the pump flow was reduced gradually to 500 ml/min for adult patients and 20--25 ml/kg/min for pediatric patients. Finally, ECMO was withdrawn when sustained stability was noted in a patient\'s hemodynamic status [@pone.0042687-Wu1].

Statistical analysis {#s2d}
--------------------

Descriptive statistics are expressed as means ± standard deviation (SD) unless otherwise stated. Primary analysis compared hospital survivors with non-survivors. All variables were tested for normal distributions using the Kolmogorov-Smirnov test. The Student *t*-test was applied to compare means of continuous variables and normally distributed data; otherwise, the Mann-Whitney *U* test was employed. Categorical data were tested using the χ^2^ test. Risk factors were assessed via univariate analysis, and statistically significant (*p*\<0.05) variables were subjected to multivariate analysis via multiple logistic regression with forward data elimination.

Calibration was assessed using the Hosmer-Lemeshow goodness-of-fit test to compare the number of observed and predicted deaths in risk groups for the entire range of death probabilities. Discrimination was assessed using the area under the receiver operating characteristic curve (AUROC). The AUROCs were compared using a nonparametric approach. AUROC analysis was also utilized to calculate cutoff values, sensitivity, specificity, and overall correctness. Finally, cutoff points were calculated by obtaining the best Youden index (sensitivity+specificity −1). Cumulative survival curves as a function of time were generated utilizing the Kaplan-Meier approach and compared using the log rank test. All statistical tests were two-tailed, with the level of significance set to *p* less than 0.05. Data were analyzed using SPSS 13.0 for Windows (SPSS, Inc., Chicago, IL, USA).

Results {#s3}
=======

Subject characteristics {#s3a}
-----------------------

The study population comprised 119 patients who were successfully weaned from ECMO support at the CVS ICU between July 2006 and October 2010. Patient median age was 50 years old; 82 patients were male (69%) and 37 were female (31%). In total, 112 patients were adults (94%) and seven were children or neonates (6%). Overall in-hospital mortality was 26% (31/119). [Table 1](#pone-0042687-t001){ref-type="table"} lists patient demographic data and the clinical characteristics of both survivors and non-survivors. [Table 2](#pone-0042687-t002){ref-type="table"} lists primary diagnosis for intensive care unit admission and the primary reason for ECMO support. The most frequent indication for ECMO support in this patient subset was cardiogenic shock (77%).

10.1371/journal.pone.0042687.t001

###### Patients\' demographic data and clinical characteristics according to in-hospital mortality.
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                                                                                      All Patients (n = 119)   Survivors (n = 88)   Non-survivors (n = 31)      *p*
  ---------------------------------------------------------------------------------- ------------------------ -------------------- ------------------------ ------------
  Age (years)                                                                                 50±19                  48±19                  54±20            NS (0.121)
  Gender (M/F)                                                                                82/37                  61/27                  21/10            NS (0.870)
  Adult/Child                                                                                 112/7                   83/5                   29/2            NS (1.000)
  Body weight (kg)                                                                            65±19                  66±19                  62±19            NS (0.379)
  Duration of ECMO support (h) \[median\]                                                  187 \[121\]            169 \[113\]            237 \[161\]           0.014
  Combination with CRRT on ECMO (Yes/No)                                                      10/109                  4/84                   6/25              0.011
  Combination with CRRT during ECMO (Yes/No)                                                  36/83                  18/70                  18/13             \<0.001
  Combination with CRRT off ECMO (Yes/No)                                                     27/92                  12/76                  15/16             \<0.001
  GCS, the day of ECMO removal (points)                                                        12±4                   13±3                   11±4              0.003
  MAP, the day of ECMO removal (mmHg)                                                         65±12                  67±12                  60±10              0.003
  UO, the day of ECMO removal (ml/day) \[median\]                                         2622 \[2865\]          2812 \[2987\]          2088 \[1487\]        NS (0.083)
  UO, at post-ECMO removal 24 h (ml/day) \[median\]                                       2247 \[2280\]          2537 \[2457\]           1408 \[986\]          0.001
  UO, at post-ECMO removal 48 h (ml/day) \[median\]                                       2167 \[2320\]          2485 \[2610\]           1270 \[952\]         \<0.001
  SCr, baseline (mg/dL) \[median\]                                                         1.2 \[1.1\]            1.2 \[1.1\]            1.4 \[1.0\]         NS (0.861)
  SCr, the day of ECMO removal (mg/dL) \[median\]                                          1.8 \[1.3\]            1.7 \[1.2\]            2.0 \[1.5\]         NS (0.058)
  SCr, at post-ECMO removal 24 h (mg/dL) \[median\]                                        1.8 \[1.3\]            1.7 \[1.2\]            2.1 \[1.6\]           0.014
  SCr, at post-ECMO removal 48 h (mg/dL) \[median\]                                        1.8 \[1.3\]            1.6 \[1.1\]            2.3 \[1.6\]           0.008
  Sodium, the day of ECMO removal (mEq/L)                                                     141±6                  141±6                  140±6            NS (0.467)
  Albumin, the day of ECMO removal (g/L)                                                     2.9±0.4                2.9±0.4                2.7±0.4             0.013
  TnI, the day of ECMO removal (ng/mL) \[median\]                                            15 \[5\]               16 \[6\]               12 \[2\]          NS (0.232)
  PaO~2~/FiO~2~, the day of ECMO removal (ratio)                                             242±142                252±135                215±161           NS (0.210)
  AaDO~2~, the day of ECMO removal (mmHg)                                                    286±150                270±148                332±150             0.050
  WBC, the day of ECMO removal (×10^3^/mL)                                                   12.9±5.4               13.1±5.4               12.4±5.4          NS (0.513)
  Hb, the day of ECMO removal (g/dL)                                                         9.9±1.0                9.9±1.0                9.7±1.2           NS (0.258)
  Platelets, the day of ECMO removal (×10^9^/L)                                               81±33                  83±32                  76±36            NS (0.317)
  AKIN~48-hour~ (stage 0/1/2/3) post ECMO removal[\*](#nt102){ref-type="table-fn"}          62/18/3/30             58/11/1/16              4/7/2/14           \<0.001
  APACHE II score, on ECMO                                                                     23±8                   22±7                   25±9              0.025
  APACHE II score, the day of ECMO removal                                                     17±7                   15±6                   22±7             \<0.001
  SOFA score, on ECMO                                                                          11±3                   11±3                   11±4            NS (0.555)
  SOFA score, ECMO removal                                                                     11±4                   10±3                   14±3             \<0.001
  OSF number, on ECMO                                                                          3±1                    3±1                    3±1             NS (0.569)
  OSF number, ECMO removal                                                                     3±1                    3±1                    4±1              \<0.001

Abbreviation: AaDO~2~, alveolar-arterial oxygen tension difference; AKIN, acute kidney injury network; APACHE II, acute physiology and chronic health evaluation II; CRRT: continuous renal replacement therapies; ECMO: extracorporeal membrane oxygenation; F, female; FiO~2~, fraction of inspired oxygen; GCS, Glasgow coma scale; Hb, hemoglobin; M, male; MAP, mean arterial pressure; NS, not significant; OSF, organ system failure; PaO2, partial pressure of oxygen; SCr, serum creatinine; SOFA, sequential organ failure assessment; TnI, troponin-I; UO, urine output; WBC, white blood cell count.

, exclude 6 patients under maintenance hemodialysis.

10.1371/journal.pone.0042687.t002

###### Primary diagnosis for intensive care unit (ICU) admission and extracorporeal membrane oxygenation (ECMO) support.
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                                           All Patients   Survivors   Non-survivors  
  --------------------------------------- -------------- ----------- --------------- ------------
  *Primary diagnosis for ICU admission*                                              
  Postcardiotomy cardiogenic shock           63 (53)       44 (50)       19 (61)      NS (0.279)
  Myocarditis                                 9 (8)         8 (9)         1 (3)       NS (0.288)
  Acute myocardial infarction                12 (10)        7 (8)        5 (16)       NS (0.194)
  Decompensated heart failure                 8 (7)         8 (9)         0 (0)       NS (0.082)
  ARDS                                       23 (19)       18 (20)       5 (16)       NS (0.600)
  Hypoxemia and shock                         4 (3)         3 (3)         1 (3)       NS (1.000)
  *Primary reason for ECMO support*                                                  
  Cardiogenic shock                          92 (77)       67 (76)       25 (81)      NS (0.606)
  ARDS                                       23 (19)       18 (20)       5 (16)       NS (0.600)
  ARDS with unstable hemodynamics             4 (3)         3 (3)         1 (3)       NS (1.000)

ARDS, acute respiratory distress syndrome; NS, not significant;

Number (%) of patients with the condition who survived or died.

Calibration, discrimination, and correlation for illness scoring systems {#s3b}
------------------------------------------------------------------------

[Table 3](#pone-0042687-t003){ref-type="table"} lists goodness-of-fit measured using the Hosmer-Lemeshow chi-square statistic of predicted mortality risk, and the predictive accuracy of the AKIN~48-hour~, APACHE II, SOFA score, and OSF number. Poor calibration of AKIN~48-hour~ (Hosmer-Lemeshow chi-square = 6.937, 2 df, *p* = 0.031) is noted. [Table 3](#pone-0042687-t003){ref-type="table"} also compares the discriminative abilities of these scoring systems. AUROC analysis confirms that the discriminative power of SOFA score exceeds that of the AKIN~48-hour~, APACHE II, and OSF number.

10.1371/journal.pone.0042687.t003

###### Comparison of calibration and discrimination of the scoring methods in predicting hospital mortality.
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                                Calibration   Discrimination                                       
  ---------------------------- ------------- ---------------- ------- ------------- -------------- ---------
  MAP, off ECMO                    7.004            8          0.536   0.696±0.054   0.591--0.801    0.003
  SOFA score, off ECMO             5.050            7          0.654   0.805±0.055   0.698--0.911   \<0.001
  UO~24--48\ hour~, off ECMO      10.844            8          0.211   0.761±0.057   0.650--0.872   \<0.001
  APACHE II, on ECMO               6.031            8          0.644   0.607±0.064   0.482--0.732    0.101
  APACHE II, off ECMO              3.180            8          0.923   0.781±0.051   0.681--0.881   \<0.001
  OSF number, off ECMO             4.555            3          0.207   0.714±0.055   0.607--0.822    0.001
  AKIN~48-hour~, off ECMO          6.937            2          0.031   0.769±0.052   0.667--0.870   \<0.001

Abbreviation: AKIN, acute kidney injury network; APACHE II, acute physiology and chronic health evaluation II; AUROC, area under the receiver operating characteristic curve; CI, confidence interval; df, degree of freedom; ECMO: extracorporeal membrane oxygenation; MAP, mean arterial pressure; OSF, organ system failure; SOFA, sequential organ failure assessment; SE, standard error; UO, urine output.

Hospital mortality and short-term prognosis {#s3c}
-------------------------------------------

Univariate analysis identified 11 ([Table 4](#pone-0042687-t004){ref-type="table"}) of 32 variables ([Table 1](#pone-0042687-t001){ref-type="table"}) as prognostically valuable. Multivariate analysis identified the following variables as having independent prognostic significance: daily urine output on the second day following ECMO removal (UO~24--48\ hour~), MAP, and SOFA score on the day of ECMO removal ([Table 4](#pone-0042687-t004){ref-type="table"}). Regression coefficients of these variables were used to calculate a logit of death for each patient, as follows:

![](pone.0042687.e001.jpg)

To assess the predictive value of each measure for hospital mortality, sensitivity, specificity, and overall correctness of prediction were determined. The SOFA score and AKIN~48-hour~ had the best Youden index and highest overall prediction correctness ([Table 5](#pone-0042687-t005){ref-type="table"}).

10.1371/journal.pone.0042687.t004

###### Variables showing prognostic significance.
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  Parameter                           Beta Coefficient   Standard error   Odds ratios (95%CI)      *p*
  ---------------------------------- ------------------ ---------------- ---------------------- ---------
  Univariate logistic regression                                                                
  GCS, off ECMO first day                  −0.190            0.058        0.827 (0.738--0.927)    0.001
  MAP, off ECMO first day                  −0.063            0.022        0.939 (0.900--0.980)    0.004
  UO~0--24\ hour~, off ECMO                −0.001            0.000        0.999 (0.999--1.000)    0.002
  UO~24--48\ hour~, off ECMO               −0.001            0.000        0.999 (0.999--1.000)   \<0.001
  Albumin, off ECMO first day              −1.447            0.605        0.235 (0.072--0.770)    0.017
  AaDO~2~, off ECMO first day              0.003             0.001        1.003 (1.000--1.006)    0.053
  AKIN~48-hour~, off ECMO                  0.744             0.180        2.105 (1.479--2.996)   \<0.001
  APACHE II score, on ECMO                 0.060             0.027        1.061 (1.006--1.119)    0.029
  APACHE II score, off ECMO                0.159             0.037        1.172 (1.089--1.262)   \<0.001
  SOFA score, off ECMO                     0.365             0.083        1.440 (1.224--1.695)   \<0.001
  OSF number, off ECMO                     0.721             0.205        2.057 (1.376--3.075)   \<0.001
  Multivariate logistic regression                                                              
  MAP, off ECMO first day                  −0.089            0.039        0.915 (0.848--0.988)    0.023
  SOFA score, off ECMO                     0.248             0.110        1.281 (1.033--1.589)    0.024
  UO~24--48\ hour~, off ECMO               −0.001            0.000        0.999 (0.999--1.000)    0.019
  Constant                                 3.080             2.973               21.760           0.300

Abbreviation: AaDO~2~, alveolar-arterial oxygen tension difference; AKIN, acute kidney injury network; APACHE II, acute physiology and chronic health evaluation II; ECMO: extracorporeal membrane oxygenation; GCS, Glasgow coma scale; MAP, mean arterial pressure; OSF, organ system failure; SOFA, sequential organ failure assessment; UO, urine output.

10.1371/journal.pone.0042687.t005

###### Prediction of subsequent hospital mortality after ECMO removal.
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  Predictive Factors                        Cutoff Point                Youden Index   Sensitivity (%)   Specificity (%)   Overall Correctness (%)
  ---------------------------- --------------------------------------- -------------- ----------------- ----------------- -------------------------
  MAP, off ECMO                  69[\*](#nt108){ref-type="table-fn"}        0.32             10                58                    34
  SOFA score, off ECMO           13[\*](#nt108){ref-type="table-fn"}        0.51             61                90                    76
  UO~24--48\ hour~, off ECMO    1468[\*](#nt108){ref-type="table-fn"}       0.50             33                17                    25
  APACHE II, on ECMO             20[\*](#nt108){ref-type="table-fn"}        0.30             77                52                    65
  APACHE II, off ECMO            18[\*](#nt108){ref-type="table-fn"}        0.44             68                76                    72
  OSF number, off ECMO           2[\*](#nt108){ref-type="table-fn"}         0.36             90                45                    68
  AKIN~48-hour~, off ECMO        0[\*](#nt108){ref-type="table-fn"}         0.53             85                67                    76

Abbreviation: AKIN, acute kidney injury network; APACHE II, acute physiology and chronic health evaluation II; ECMO: extracorporeal membrane oxygenation; MAP, mean arterial pressure; OSF, organ system failure; SOFA, sequential organ failure assessment; UO, urine output.

Value giving the best Youden index.

[Figure 1A](#pone-0042687-g001){ref-type="fig"} shows the cumulative rates of survival for the study group dichotomized by 13 SOFA points or less/14 SOFA points or more (*p*\<0.001). Cumulative survival rates differed considerably (*p*\<0.001) between non-AKI and AKI ([Figure 1B](#pone-0042687-g001){ref-type="fig"}).

![Cumulative survival rate for 119 critically ill patients based on (A) sequential organ failure assessment (SOFA) score on the day of ECMO removal and (B) acute kidney injury (AKI) or not based on changes over the course of 48 hours after ECMO removal.\
AKI defined as in the AKIN~48-hour~ classification system with stage 1, 2 and 3.](pone.0042687.g001){#pone-0042687-g001}

Discussion {#s4}
==========

The hospital mortality rate for patients who received ECMO support around 60% [@pone.0042687-Lin1]--[@pone.0042687-Chen1] and experienced successful ECMO weaning in this study was 26%. This investigation demonstrates that MAP and SOFA score on the day of ECMO removal, and daily urine amount on the second day after weaning from ECMO, were strong predictors of in-hospital mortality ([Table 4](#pone-0042687-t004){ref-type="table"}). The SOFA score had better discriminatory power than the AKIN~48-hour~, APACHE II and OSF number ([Table 3](#pone-0042687-t003){ref-type="table"}). Moreover, the SOFA score and AKIN~48-hour~ had the best Youden index and highest overall prediction accuracy ([Table 5](#pone-0042687-t005){ref-type="table"}).

Urine volume is a more sensitive marker for early detection of AKI than serum creatinine level. Decreased urine volume on the day of ECMO removal is attributed to decreased cardiac output following decannulation, and is correlated with acute cardiorenal syndrome (CRS type 1) [@pone.0042687-Ronco1]. For patients with improved systolic function, urine volume may increase gradually in the following days; for other patients, decreased urine volume progresses and causes fluid overload, which likely increases preload and may contribute to circulatory failure. Additionally, loop diuretics were usually prescribed for better diuresis in cases of decreased urine volume. Metra *et al.* [@pone.0042687-Metra1] identified the use of loop diuretics, probably by further activation of the renin-angiotensin-aldosterone system and possibly worsening intra-renal hemodynamics, as one of the modifiable in-hospital determinants of CRS type 1. Circulatory failure may further aggravate in-hospital mortality. For patients weaned from ECMO, this study adopted the best Youden index, and established a cut-off (urine volume of 1468 ml) ([Table 5](#pone-0042687-t005){ref-type="table"}). Hospital mortality rates below and above the cutoff value of 1468 ml of daily urine volume on the second day of ECMO removal were 59.5% (22/37) and 12.5% (9/72) (*p*\<0.001), respectively.

Mehta and colleagues [@pone.0042687-Mehta2] reported that blood pressure is a key bedside tool for predicting postoperative dialysis risk in patients undergoing cardiac surgery. Hypotension is related to worsening renal function for patients weaned from ECMO support. Damaged cardiac function leads to low cardiac output and, therefore, hypoperfusion, and may precipitate pre-renal AKI, which, if not promptly corrected, can evolve into intrinsic AKI and even cortical necrosis, resulting in irreversible loss of renal function [@pone.0042687-Schrier1], [@pone.0042687-Cadnapaphornchai1]. Analytical results demonstrate that MAP on the day of ECMO removal is an independent risk factor for patients weaned from ECMO. This investigation applied the best Youden index and a recognized MAP cut-off value of 69 mmHg ([Table 5](#pone-0042687-t005){ref-type="table"}). Hospital mortality rates differed considerably according to the best Youden index was below or above the cutoff of 69 mmHg of MAP (34.6% *vs.* 9.8%, *p* = 0.003).

Ceriani *et al.* [@pone.0042687-Ceriani1] concluded that SOFA was applicable in cardiac surgery without requiring specific modifications based on the good results they obtained in 218 patients. Belohlavek and colleagues [@pone.0042687-Belohlavek1] reported that patients who died on ECMO had higher SOFA scores (14.8±1.6 vs. 10.8±1.5; *p* = 0.0065). Wu *et al.* [@pone.0042687-Wu2] also stated that SOFA score before ECMO implantation exceeding 14 predicted mortality. For patients successfully weaned from ECMO, this study adopted the best Youden index, and established a cut-off value of 13 for SOFA score ([Table 5](#pone-0042687-t005){ref-type="table"}). Hospital mortality rates differed significantly below and above this cut-off value (13.2% *vs.* 67.9%, *p*\<0.001). This study demonstrated that SOFA score exceeding 13 on the day of ECMO removal predicted hospital mortality, a result compatible with previous studies.

Acute kidney injury following cardiac surgery is a well-recognized complication that occurs in up to 40% of patients and requires dialysis in 1% of cases [@pone.0042687-Mariscalco1]. Patients who develop AKI have high mortality and resource utilization. Emerging evidence suggests that even small increases in creatinine following cardiac surgery are associated with significantly increased mortality. Following weaning from ECMO for 48 hours, hospital mortality rates differed significantly between patients with AKI *vs.* those without AKI (45.1% *vs.* 6.5%, *p*\<0.001).

Despite the promising study results, this study has several important limitations. First, this was a retrospective study performed at a single tertiary-care medical center, limiting the generalizability of the findings. Second, this retrospective study suffered difficulties associated with the unavailability of certain laboratory data, including serum sodium, albumin, and troponin-I levels. Third, the patient group comprised patients weaned from ECMO excluding those who died within 48 hours of weaning; therefore, our results may not be directly extrapolated to other patient populations. Furthermore, the prognostic markers results are only applied for patients surviving 48 hours of ECMO removal. Fourth, the patient population contained a high proportion of cardiogenic shock patients (77%) ([Table 2](#pone-0042687-t002){ref-type="table"}) and may present as a special subgroup of patients on ECMO. Besides, different prognostic markers might be identified in ARDS patients (23%) weaned from ECMO support, such as alveolar-arterial O~2~-tension difference or PaO2/FiO2 ratio. Fifth, because of the relatively small sample size, sensitivity, specificity and the predictive accuracies derived from the "best cut-off point" require further external validation. Sixth, the predictive accuracy of logistic regression models has its own limitations. Finally, sequential measurement of these scoring systems (*such as*, daily or weekly) may reflect the dynamic aspects of clinical diseases, thus providing superior information for outcome prediction.

In conclusion, this study observed a hospital mortality rate of 26% in critical ill patients weaned from ECMO support. According to the analytical results, the risk of mortality increases with decreasing urine volume, low MAP, and high SOFA score at the time of ECMO removal. Our data also demonstrate the good discriminative power of SOFA score to predict hospital mortality of critically ill patients weaned from ECMO support. We recommend physicians use SOFA score to assess short-term prognosis in this subset of patients.
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